SELECT FROM MENU

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

Hidehito Horinouchi

Hidehito Horinouchi

National Cancer Center Hospital, Tokyo

Dr Hidehito Horinouchi is a medical oncologist and Assistant Chief of the Department of Thoracic Oncology at the National Cancer Center Hospital in Tokyo, Japan. His work centres on new drug development and multimodality treatment of thoracic malignancies, spanning chemotherapy, radiotherapy, surgery and immunotherapy.

He has helped plan and run many clinical trials in thoracic oncology and serves as Secretary General of the Lung Cancer Study Group within the Japan Clinical Oncology Group (JCOG). He is Deputy Chief of the National Cancer Center’s Center for Education and Professional Career Development and holds education committee roles with the Japanese Society of Medical Oncology (JSMO), the Japan Lung Cancer Society (JLCS) and the International Association for the Study of Lung Cancer (IASLC).

Connect

Hidehito Horinouchi

Featured in

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates